We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

22 hedge funds and large institutions have $4.64M invested in AIM ImmunoTech in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more capital invested

Capital invested by funds: $1.45M → $4.64M (+$3.19M)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

10% more funds holding

Funds holding: 20 → 22 (+2)

Holders
22
Holders Change
+2
Holders Change %
+10%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
4
Reduced
2
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.13M
2
Morgan Stanley
Morgan Stanley
New York
+$1.11M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$686K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$376K
5
Northern Trust
Northern Trust
Illinois
+$140K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$498K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$327K
3
Jane Street
Jane Street
New York
-$72K
4
Osaic Holdings
Osaic Holdings
Arizona
-$56.6K
5
Goldman Sachs
Goldman Sachs
New York
-$38K

AIM Hedge Fund Activity: Q2 2020 in Review

22 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2020, worth a combined $4.64M — up 220% from $1.45M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new AIM positions and 10 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $1.13M. The largest seller was Millennium Management, exiting entirely with an estimated $498K sold.

  • 22 institutional investors held AIM ImmunoTech (AIM) as of Q2 2020, up from 20 in Q1 2020.
  • Funds reported $4.64M of AIM ImmunoTech stock for Q2 2020, up 220% quarter-over-quarter.
  • 12 funds opened new AIM ImmunoTech positions in Q2 2020 and 10 closed out, a net change of +2 holders.
  • The largest AIM ImmunoTech buyer in Q2 2020 was BlackRock, an estimated $1.13M added.
  • The largest AIM ImmunoTech seller in Q2 2020 was Millennium Management, an estimated $498K sold.

Based on aggregated 13F filings for Q2 2020.